Myasthenia gravis adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 7,765 adverse event reports that record the MedDRA preferred term Myasthenia gravis. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 1,021 reports in the 12 months to June 2026 and 1,062 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 603 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 1,021 (0.1%) record this term. Reports for female patients were 39.8% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 142 drug pages with 50 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Myasthenia gravis name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		190
Albuterol	beta2-Adrenergic agonist	134
Albuterol sulfate	beta2-Adrenergic agonist	110
Allopurinol	Xanthine oxidase inhibitor	173
Aluminum hydroxide		51
Aminobenzoic Acid		95
Amiodarone		110
Amiodarone hydrochloride	Antiarrhythmic	132
Amlodipine	Calcium channel blocker	53
Amlodipine besylate	Dihydropyridine calcium channel blocker	63
Aranesp	Erythropoiesis-stimulating agent	150
Ascorbic acid	Vitamin C	64
Atezolizumab	Programmed death Receptor-1 blocking antibody	77
Atorvastatin		131
Azathioprine	Purine antimetabolite	55
Betamethasone		124
Betamethasone dipropionate	Corticosteroid	66
Biotin	Arteriolar vasodilator	91
Bisacodyl		132
Breo Ellipta	Corticosteroid	74
Calcitriol	Vitamin D3 analog	154
Calcium carbonate	Blood coagulation factor	63
Carboplatin	Platinum-based drug	67
Ceftriaxone	Cephalosporin antibacterial	106
Ceftriaxone sodium	Cephalosporin antibacterial	129
Chloramphenicol		73
Chlorpheniramine		53
Cortisone	Corticosteroid	54
Dalteparin sodium	Anti-coagulant	104
Darbepoetin alfa	Erythropoiesis-stimulating agent	52
Dexilant	Proton pump inhibitor	126
Dexlansoprazole	Proton pump inhibitor	79
Dextrose		167
Dextrose Sodium Chloride		83
Dietary Supplement		83
Diprosone		65
Dipyrone		133
Distigmine Bromide		141
Dobutamine	beta-Adrenergic agonist	123
Dobutamine hydrochloride	beta-Adrenergic agonist	68
Docusate sodium		97
Dulcolax	Osmotic laxative	105
Efgartigimod alfa	Neonatal Fc receptor blocker	58
Enbrel	Tumor necrosis factor blocker	69
Fiasp	Insulin analog	57
Fluticasone	Corticosteroid	72
Fluticasone furoate	Corticosteroid	89
Fluticasone Furoate Vilanterol Trifenatate		80
Fluticasone Propionate Salmeterol Xinafoate		60
Fosrenol	Phosphate binder	78
Fragmin	Anti-coagulant	127
Furazolidone		151
Gabapentin	Anti-epileptic agent	219
Heparin Calcium		93
Heparin sodium	Anti-coagulant	128
Herbals		114
Herbals Paullinia Cupana Seed		129
Human immunoglobulin g	Human immunoglobulin G	124
Humira		110
Hydrocortisone	Corticosteroid	74
Hydromorphone		127
Hydromorphone hydrochloride	Opioid agonist	134
Insulin aspart	Insulin analog	131
Insulin degludec	Insulin analog	105
Ipilimumab	CTLA-4-directed blocking antibody	100
Ipratropium		112
Ipratropium bromide	Anticholinergic	166
Keytruda	Programmed death Receptor-1 blocking antibody	364
Lansoprazole	Proton pump inhibitor	147
Lanthanum carbonate	Phosphate binder	144
Lidocaine	Amide local anesthetic	76
Maalox Antacid		55
Magnesium carbonate		68
Magnesium oxide	Calculi dissolution agent	106
Mannitol		117
Melatonin		151
Mestinon	Cholinesterase inhibitor	98
Metamizole sodium		87
Methotrexate	Folate analog metabolic inhibitor	53
Methylprednisolone	Corticosteroid	61
Metronidazole	Nitroimidazole antimicrobial	176
Mycophenolate mofetil	Antimetabolite immunosuppressant	131
Nitroglycerin	Nitrate vasodilator	54
Nivolumab	Programmed death Receptor-1 blocking antibody	220
Norepinephrine	Catecholamine	101
Norepinephrine bitartrate	Catecholamine	116
Novorapid		67
Ondansetron	Serotonin-3 receptor antagonist	153
Opdivo	Programmed death Receptor-1 blocking antibody	255
Oseltamivir	Neuraminidase inhibitor	51
Oseltamivir phosphate	Neuraminidase inhibitor	108
Otrivin		132
Pembrolizumab	Programmed death Receptor-1 blocking antibody	158
Phytonadione		151
Polyethylene glycol 3350	Osmotic laxative	118
Polyethylene glycol 4000		93
Polyethylene Glycols		93
Potassium chloride	Osmotic laxative	127
Prednisolone	Corticosteroid	90
Prednisone	Corticosteroid	270
Prevacid	Proton pump inhibitor	113
Propylene glycol		73
Pyridostigmine	Cholinesterase inhibitor	96
Pyridoxine hydrochloride		115
Ramipril	Angiotensin converting enzyme inhibitor	64
Ravulizumab	Complement inhibitor	65
Riboflavin		52
Rituximab	CD20-directed cytolytic antibody	146
Rosuvastatin	HMG-CoA reductase inhibitor	63
Rozanolixizumab	Neonatal Fc receptor blocker	217
Rystiggo	Neonatal Fc receptor blocker	84
Simvastatin	HMG-CoA reductase inhibitor	198
Sodium bicarbonate	Osmotic laxative	63
Sodium chloride	Osmotic laxative	68
Sodium citrate	Anti-coagulant	121
Sodium ferric gluconate complex	Parenteral iron replacement	137
Sodium phosphate		63
Sodium phosphate monobasic		125
Sodium picosulfate		134
Soliris	Complement inhibitor	513
Tecentriq	Programmed death Receptor-1 blocking antibody	62
Theophylline	Methylxanthine	55
Trelegy Ellipta	Anticholinergic	90
Tresiba	Insulin analog	79
Ultomiris	Complement inhibitor	388
Umeclidinium bromide		115
Umeclidinium Bromide Vilanterol Trifenatate		67
Vasopressin		121
Vilanterol trifenatate		105
Vitamin B6		67
Vitamin c	Vitamin C	99
Vitamin e	Vitamin C	80
Vitamin K1		125
Vyvgart	Neonatal Fc receptor blocker	686
VYVGART Hytrulo	Endoglycosidase	59
Warfarin	Vitamin K antagonist	100
Warfarin sodium	Vitamin K antagonist	69
Xantofyl Palmitate		105
Yervoy	CTLA-4-directed blocking antibody	118
Zilbrysq	Complement inhibitor	83
Zilucoplan	Complement inhibitor	204
Zocor	HMG-CoA reductase inhibitor	109

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 55 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Myasthenia gravis name, in order of name
Class	Reports with this term
Acetylcholine release inhibitor	53
Amide local anesthetic	91
Aminosalicylate	50
Angiotensin 2 receptor blocker	61
Angiotensin converting enzyme inhibitor	64
Anti-coagulant	529
Anti-epileptic agent	225
Antiarrhythmic	132
Anticholinergic	278
Antimetabolite immunosuppressant	195
Arteriolar vasodilator	91
Atypical antipsychotic	74
beta-Adrenergic agonist	191
beta2-Adrenergic agonist	264
Blood coagulation factor	130
Calcineurin inhibitor immunosuppressant	101
Calcium channel blocker	58
Calculi dissolution agent	141
Catecholamine	217
CD20-directed cytolytic antibody	200
Cephalosporin antibacterial	239
Cholinesterase inhibitor	194
Complement inhibitor	993
Corticosteroid	1,097
CTLA-4-directed blocking antibody	251
Dihydropyridine calcium channel blocker	63
Erythropoiesis-stimulating agent	202
Fluoroquinolone antibacterial	87
Folate analog metabolic inhibitor	70
Histamine-1 receptor antagonist	51
HMG-CoA reductase inhibitor	447
Human immunoglobulin G	183
Insulin analog	403
Kinase inhibitor	102
Methylxanthine	55
Microtubule inhibitor	56
Neonatal Fc receptor blocker	770
Neuraminidase inhibitor	198
Nitrate vasodilator	54
Nitroimidazole antimicrobial	178
Opioid agonist	175
Osmotic laxative	512
Phosphate binder	222
Platinum-based drug	94
Programmed death Ligand-1 blocker	126
Programmed death Receptor-1 blocking antibody	1,145
Proton pump inhibitor	521
Purine antimetabolite	57
Serotonin-3 receptor antagonist	198
Tumor necrosis factor blocker	139
Vascular endothelial growth factor inhibitor	79
Vitamin C	243
Vitamin D3 analog	154
Vitamin K antagonist	169
Xanthine oxidase inhibitor	173

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Myasthenia gravis, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Myasthenia gravis
Age	Reports	Share
Under 2	6	0.1%
2 to 11	35	0.5%
12 to 17	46	0.6%
18 to 44	715	9.2%
45 to 64	1,268	16.3%
65 to 74	1,190	15.3%
75 and over	1,261	16.2%
Age not given	3,244	41.8%

Sex of the patient in the reports that record Myasthenia gravis
Sex	Reports	Share
Female	3,087	39.8%
Male	2,951	38%
Unknown or not given	1,727	22.2%

Age and sex are as the report gives them. 50.1% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Myasthenia gravis: adverse event reports that record this term. https://reportedreactions.com/reaction/myasthenia-gravis/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Myasthenia gravis mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page